This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia
Leukemia Open Access 25 March 2022
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Endnote: the correct statistical term is estimate, not guess.
Galton F. Vox Populi. Nature. 1907;75:450–51.
Endnote: Galton considered the butchers to be experts.
Wallis KF. Revisiting Francis Galton’s forecasting competition. Stat Sci. 2014;29:420–24.
https://www.npr.org/sections/money/2015/08/07/429720443/17-205-people-guessed-the-weight-of-a-cow-heres-how-they-did. Accessed 8 Jan 2018.
Surowiecki J. The wisdom of crowds: why they are smarter than the few and how collective wisdom shapes business, economics, societies and nations. New York, NY: Anchor books; 2004.
Jacobs C, Graham JD, Makarski J, Chasse M, Fergusson D, Hutton B, et al. Clinical Practice Guidelines and consensus statements in oncology—an assessment of their methodological quality. PLoS ONE. 2014. https://doi.org/10.1371/journal.pone.0110469.
Kea B, Sun BJ. Consensus development for healthcare professionals. Intern Emerg Med. 2015;10:373–83.
Endnote: We acknowledge the truth may not be knowable with complete accuracy and precision because of 2 unavoidable considerations: measurement, error and chance.
Gale RP, Park RE, Dubois R, Bitran J, Buzdar A, Hortobagyi G, et al. Delphi-consensus panel analysis of appropriateness of high-dose chemotherapy and blood cell or bone marrow autotransplants in women with breast cancer. Clin Transplant. 2000;14:32–41.
Tallman MS, Gray R, Robert NJ, LeMaistre CF, Osborne CK, Vaughn WP, et al. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med. 2003;349:17–26.
Stadtmauer EA, O’Neill A, Goldstein LJ, Crilley PA, Mangan KF, Ingle JN, et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation in metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N Eng J Med. 2000;342:1069–76.
Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Rohenhuis S, et al. High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol. 2011;29:3214–23.
Prasad V, Gail V, Cifu A. The frequency of medical reversal. Arch Intern Med. 2011;171:1675–6.
Ioannidis JP. Contradicted and initially stronger effects in higher cited clinical research. JAMA. 2005;294:218–28.
Space for BR Med J. http://bestpractice.bmj.com/info/us/
Prasad VK, CIfu AS. Ending medical reversal: improving outcomes, saving lives. 1st Edition. Baltimore, MD: John Hopkins University Press; 2005.
Howard DH, Kenline C, Lazarus HM, Lemaistre CF, Maziarz RT, McCarthy PL Jr, et al. Abandonment of high-dose chemotherapy/hematopoietic cell transplants for breast cancer following negative trial results. Health Serv Res. 2011;46:1762–77.
https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/statin-use-in-adults-preventive-medication1. Accessed 6 Jan 2018.
Al-Lamee R, Thompson D, Dehbi HM, Sen S, Tang K, Davies J, et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomized controlled trial. Lancet. 2018;391:31–40.
https://www.nytimes.com/2017/12/27/upshot/what-we-mean-when-we-say-evidence-based-medicine.html. Accessed 30 Dec 2017.
Mortensen MB, Nordestgaard BG. Comparison for statin use in primary prevention in a contemporary general population. Ann Intern Med. 2018;168: 85-92.
https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf. Accessed 30 Dec 2017.
Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FS, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47.
Browers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ. 2010;182:E839–42.
Graham RMM, Miller Wolman D, Greenfield S, Steinberg E, Editors.. Clinical practice guidelines we can trust: Institute of Medicine (US) Committee on Standards for Developing Trustworthy Clinical Practice Guidelines. Washington (DC): National Academies Press; 2011. Committee on Standards for developing trustworthy clinical practice guidelines
Guidelines International Network. http://www.g-i-n.net/. Accessed 19 Dec 2017.
http://www.cebm.net. Accessed 31 Dec 2017.
http://www.gradeworkinggroup.org/. Accessed 31 Dec 2017.
Acknowledgements
Prof. Hillard Lazarus (Case Western Reserve Univ.) kindly reviewed the typescript. RPG acknowledges support from the National Institute of Health Research (NIHR) Biomedical Research Centre funding scheme.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
RPG is a part-time employee of Celgene Corp.
Rights and permissions
About this article
Cite this article
Barosi, G., Gale, R.P. Is there expert consensus on expert consensus?. Bone Marrow Transplant 53, 1055–1060 (2018). https://doi.org/10.1038/s41409-018-0128-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-018-0128-2
This article is cited by
-
Myelodysplastic syndromes
Nature Reviews Disease Primers (2022)
-
Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia
Leukemia (2022)
-
The impact of cult behavior on haematopoietic cell transplant practices: believers and non-believers
Bone Marrow Transplantation (2022)
-
Granulocyte transfusions in haematopoietic cell transplants and leukaemia: the phoenix or beating a dead horse?
Bone Marrow Transplantation (2021)
-
Response to “Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions” by Heidel et al.
Leukemia (2018)